Twist Bioscience
Twist Bioscience raises $200M Convertible Note at $4B valuation
Twist Bioscience: Convertible Note Funding Round
Twist Bioscience has successfully raised $200M in Convertible Note funding, reaching a valuation of $4B.
Company Overview
Synthetic DNA manufacturing
Funding Details
The Convertible Note round was led by Temasek Holdings, with participation from Fidelity, Paladin Capital Group, Casdin Capital.
Company Information
- Headquarters: 681 Gateway Boulevard, South San Francisco, CA 94080
- Founded: 2013
- Employees: 600+
- Category: Biotech
Investment
Twist Bioscience plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Temasek Holdings: Verified investor in Convertible Note
- Fidelity: Verified investor in Convertible Note
- Paladin Capital Group: Verified investor in Convertible Note
- Casdin Capital: Verified investor in Convertible Note
Company Info
Investors (4)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free